Glucose Monitor Useful In Identifying Asymptomatic Diabetics, MiniMed Says
This article was originally published in The Gray Sheet
MiniMed's planned introduction of a consumer version of its continuous home glucose monitor (CGMS) in 2001 is unlikely to result in the phasing-out the professional version introduced in July, given the recent physician debate about what separates a diabetic patient from a "normal" patient.
You may also be interested in...
Firm's Model 508 insulin infusion pumps distributed between Oct. 4 and Nov. 18, 1999 could have "a rare and minor software error" that could lead to a patient receiving an incorrect dosage, the firm announced Nov. 19. Notification containing programming instructions has been sent to all users who purchased the pump during the relevant time period and new systems contain an upgraded version of the software. FDA has been notified but no adverse event reports have been filed, according to the company
The annual cost of insulin therapy administered through a subcutaneous infusion pump is $3,329, the Health Care Financing Administration estimates in a Medicare national coverage decision for the devices in Type I diabetes announced Sept. 24. An effective date will be specified in an upcoming instruction to carriers.
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.